Antibiotic Prophylaxis in Rhinoplasty

Not Recruiting

Trial ID: NCT04194216

Age - 18 Years-N/A Gender - ALL Accepting Healthy Volunteers - No

Purpose

This study compares the efficacy of a single intra-operative (intravenous) dose of "cephalexin" (first generation cephalosporin) or "clindamycin" (lincosamides), alone versus both intra-operative (intravenous) dose of "cephalexin" (first generation cephalosporin) or "clindamycin" (lincosamides) and postoperative oral dose of "cephalexin" or "clindamycin" use in nasal surgery.

Official Title

Comparison of Outcomes in Rhinoplasty With the Use of Intraoperative Versus Postoperative Antibiotics

Stanford Investigator(s)

Sam P. Most, MD, FACS
Sam P. Most, MD, FACS

Professor of Otolaryngology - Head & Neck Surgery (OHNS)

Eligibility

Inclusion Criteria:

Adult patients (aged 18years and older)

Exclusion Criteria:

* Prior rhinoplasty
* Any exogenous (non-nasal) grafts/implants
* Immune deficiency (DM, meds, other)
* History of radiotherapy to nose

View More
View Less

Intervention(s):

drug: Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg.

drug: Intra-operative single dose (iv) of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg (every 4 hours) or "clindamycin" 150mg(every 6 hours) for 3 days

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Sam P Most, MD
6507363223

©2024 Stanford Medicine